Trial · NCT06867822
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
NCT06867822, Phase 1, Suspended, University of Alabama at Birmingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of ProAgio in Advanced/Metastatic Colorectal Cancer. Trials, record NCT06867822. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06867822
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
- NCT number
- NCT06867822
- Status
- Suspended
- Phases
- Phase 1
- Enrollment
- 27 participants, estimated
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Advanced Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- ProAgio, FOLFIRI, Bevacizumab
- First posted
- 2025-03-10
- Last updated
- 2026-10-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in NCI CTCAE scale version 5.0 | Baseline, up to 18 months | National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE. |
| Secondary | Evaluate the pharmacokinetics of ProAgio | Baseline, up to 10 months | Assessed by measurement of serum levels of ProAgio over time following IV infusion. |
| Secondary | Assessment of anti-tumor activity by measuring objective response rate (ORR) | up to 12 weeks | The proportion of participants with partial response or complete response. RECIST 1.1 will be used to assess ORR. |
| Secondary | Progression free survival (PFS) - duration of time from start of treatment to time of progression or death, whichever occurs first. | up to 18 months | Determined from date of 1st dose of study drug to disease progression and/or death from any cause. |
| Secondary | Overall survival (OS) - the length of time from start of treatment until death from any cause. | up to 18 months | Determined from date of 1st dose of study drug to death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06867822
GET https://conductscience.org/api/trials/v1/NCT06867822/registered